GlassScriptPhysician profile
Pamela Bendickson
NPI 1801421631
$1,033.33
in general payments reported to CMS, 2019-2025
14 companies · $209 in 2025
The $209 reported for 2025 was more than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $38.78 · 2024: $786 · 2025: $209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $995.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $994.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $188.38 | 2024 | |
| Argenx US, INC. | $171.56 | 2024-2025 | Vyvgart Hytrulo |
| Ucb, INC. | $142.08 | 2024 | Rystiggo, Nayzilam |
| Pfizer INC. | $115.34 | 2024-2025 | |
| Chiesi USA, INC. | $103.79 | 2025 | Cleviprex |
| Lilly USA, LLC | $69.16 | 2024 | Kisunla, Emgality |
| Emd Serono, INC. | $53.34 | 2024 | |
| Neurocrine Biosciences, INC. | $51.33 | 2024 | Ingrezza |
| Eisai INC. | $31.35 | 2024 | |
| Jazz Pharmaceuticals INC. | $26.13 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $26.06 | 2024 | Austedo Xr |
| Aesculap, INC. | $20.45 | 2021 | |
| Orthofix Medical, INC. | $18.33 | 2021 | |
| Lundbeck LLC | $16.03 | 2025 | Vyepti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pamela Bendickson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.